Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. It is a white odorless powder, slightly hygroscopic and soluble in water to 50% at pH 6.
ELMIRON® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.
Media Articles Related to Elmiron (Pentosan Polysulfate)
Towards better treatment of cystitis
Source: Urology / Nephrology News From Medical News Today [2016.08.31]
Every year, millions of people are treated for cystitis, but despite its prevalence, the disease is still a scientific mystery.
Interstitial Cystitis (IC)
Source: MedicineNet Narcolepsy Specialty [2016.06.08]
Title: Interstitial Cystitis (IC)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/8/2016 12:00:00 AM
Bladder Infection (Cystitis)
Source: MedicineNet Interstitial Cystitis Specialty [2015.10.30]
Title: Bladder Infection (Cystitis)
Category: Diseases and Conditions
Created: 4/25/2011 12:00:00 AM
Last Editorial Review: 10/30/2015 12:00:00 AM
Gallbladder Disease: What You Need to Know
Source: Endocrinology News From Medical News Today [2016.08.22]
The gallbladder can be affected by diseases such as gallstones and cholecystitis. Learn about their diagnosis, treatment, and prevention with this article.
Published Studies Related to Elmiron (Pentosan Polysulfate)
Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: a double-blind, randomised, placebo-controlled trial. [2009.06]
Idiopathic feline lower urinary tract disease (FLUTD) is a common clinical entity where different treatments, for example glycosaminoglycans (GAGs) such as pentosan polysulphate (PPS), are advocated. However, few treatments have been investigated by well-controlled clinical trials... Whether or not PPS may be beneficial in a subpopulation of cats with continuous or frequently recurring clinical signs may be elucidated in forthcoming double-blind, randomised and placebo-controlled trials including only this subpopulation of cats.
Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. [2008.04]
OBJECTIVES: To measure urinary epidermal growth factor (EGF) and interleukin-6 (IL-6) levels in painful bladder syndrome/interstitial cystitis (PBS/IC) patients randomized to either cyclosporine A (CyA) or pentosan polysulfate sodium (PPS) treatment for 6 months and compare the results with treatment response... CONCLUSIONS: Treatment of PBS/IC patients with CyA resulted in significantly decreased urinary levels of EGF. Interleukin-6 levels did not change significantly in all treated patients after either CyA or PPS treatment, but in older patients the levels were reduced after CyA treatment.
Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. [2008.01]
OBJECTIVES: Interstitial cystitis (IC) is a chronic, debilitating condition that is often associated with late diagnosis and a delay in initiation of appropriate IC-specific therapy. The purpose of this study was to determine whether the length of time from initial diagnosis to start of treatment impacts subsequent symptom improvement... CONCLUSIONS: Initiation of PPS treatment within 6 months of establishing the diagnosis of IC may be associated with greater improvement in patient symptoms and symptom bother.
Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. [2008.01]
PURPOSE: We examined the safety and the efficacy of a combination of intravesical and oral pentosan polysulfate sodium in comparison to only oral pentosan polysulfate sodium in treating interstitial cystitis... CONCLUSIONS: The use of intravesical pentosan polysulfate sodium simultaneously with oral pentosan polysulfate sodium is a safe and effective therapeutic option. These findings will open a new option for patients with interstitial cystitis to reduce their severely devastating symptoms and to improve their quality of life and well-being.
Evaluation of pentosan polysulfate sodium in the postoperative recovery from cranial cruciate injury in dogs: a randomized, placebo-controlled clinical trial. [2007.04]
OBJECTIVE: To evaluate the efficacy of pentosan polysulfate (PPS) for improving the recovery period and mitigate the progression of osteoarthritis (OA) of the canine stifle after extracapsular stabilization of cranial cruciate ligament (CCL) injuries. STUDY DESIGN: Randomized, blinded, placebo-controlled clinical trial. ANIMALS: Dogs (n=40) with unilateral CCL instability... CONCLUSIONS: PPS administered after stabilization of the cruciate deficient stifle may prove to be a useful adjunctive treatment option, although further studies are necessary to substantiate this claim.
Clinical Trials Related to Elmiron (Pentosan Polysulfate)
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis [Terminated]
The purpose of this study is to evaluate the safety and effectiveness of pentosan
polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day,
and placebo for 24 weeks for the relief of bladder pain or discomfort associated with
Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome [Recruiting]
The efficacy of pentosan polysulfate sodium, hydrodistension and combination therapy in
patients with bladder pain syndrome.
An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland [Completed]
Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action [Recruiting]
This is a study for patients that have a condition called Interstitial Cystitis, also known
as Painful Bladder Syndrome. Patients would have tried at least two different therapies,
unsuccessfully,(eg. medications, pelvic floor physical therapy)
The purpose of this research project is to study the immunosuppressive drug Cyclosporine in
patients with Interstitial Cystitis to assess how well it works, what the side effects are
and what is its mechanism of action. Cyclosporine is a drug that is FDA-approved to prevent
organ rejection after kidney, liver, and heart transplant but is not approved by the FDA for
Interstitial Cystitis. Several research studies have been published showing that
Cyclosporine can improve the symptoms of Interstitial Cystitis, that it works better than a
placebo ("sugar pill" or inert treatment) and that it works more effectively than Pentosan
Polysulfate (Elmiron), which is an FDA approved therapy. The dose of Cyclosporine used in
these studies on Interstitial Cystitis are much lower that the doses used to prevent
rejection in transplant patients.
Based on these studies, the American Urological Association has recently published treatment
guidelines that recommend Cyclosporine therapy for Interstitial Cystitis after the failure
of other more conservative therapies and medications. Nevertheless, much is not known about
using Cyclosporine therapy for Interstitial Cystitis including the mechanism of action, the
ideal dose, how best to monitor for side effects and in particular whether kidney damage can
occur at the low doses used in these studies. In this study, to examine the mechanism of
action, blood and urine samples will be collected before, during and after therapy to look
at "biomarkers", chemical substances that can be associated with inflammation and tissue
injury. We will also test effects of therapy on skin sensation and pain perception because
the molecule which Cyclosporine binds to (calcineurin) is also found in nerves that conduct
This study is only being done at the Cleveland Clinic and will involve about 30 patients
with Interstitial Cystitis.
Reports of Suspected Elmiron (Pentosan Polysulfate) Side Effects
Drug Ineffective (13),
Gastrooesophageal Reflux Disease (11),
Abnormal Loss of Weight (10),
Incorrect Dose Administered (10),
Abdominal Pain Upper (9),
Cystitis Interstitial (9),
Blood Cholesterol Increased (9),
Product Quality Issue (9), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Elmiron has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Elmiron review by 45 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || Interstitial Cystitis|
|Dosage & duration:|| || 100 mg taken 3 x/day for the period of 5 years|
|Other conditions:|| || Lyme disease, hypothyroid|
|Other drugs taken:|| || too many to name - Detrol LA, Zyrtec, etc...|
|Benefits:|| || relief of symptoms of Interstitial cystitis, including pain and frequency of urination|
|Side effects:|| || Initially - feeling of wooziness, nausea, tiredness. This wore off after 6-8 weeks. |
|Comments:|| || Relieved my symptoms of Interstitial Cystitis significantly after 1 year or so on the drug. Even within 3 months it greatly reduced the pain associated with the disease and decreased the number of times I had to use the bathroom from >40 per day to <20 per day. With continued use, I believe it helped reduce inflammation/mast cell production in my bladder, and along with dietary changes and treatment for infections to my bladder wall lining caused by Lyme disease related organisms, Elmiron allowed my bladder to heal to some degree, reducing my symptoms further and my incidence of urinating to <10 times per day on average.|
Page last updated: 2016-08-31